The connective tissue diseases (CTDs) are a group of systemic disorders characterized by autoimmunity and autoimmune-mediated organ damage. The lung is a frequent target and all components of the respiratory system are at risk. Interstitial lung disease (ILD) represents a broad group of diffuse parenchymal lung injury patterns characterized by varying degrees of inflammation and fibrosis, is a common manifestation of CTD particularly common in systemic sclerosis, polymyositis/dermatomyositis, and rheumatoid arthritis, and is a leading cause of significant morbidity and mortality. The lung injury patterns of CTD-associated ILD (CTD-ILD) mirror those of idiopathic interstitial pneumonia and may arise at any time during the course of the CTD or may be the first manifestation of CTD. Patients with CTD that present with respiratory failure often present significant diagnostic dilemmas. Thorough and comprehensive assessments to exclude respiratory *infection, acute interstitial pneumonia, medication toxicity, pulmonary embolism, cardiac dysfunction, and diffuse alveolar hemorrhage are the fundamental components for the evaluation of such patients. Furthermore, patients with CTD are also at risk of acute exacerbations of underlying ILD. Acute exacerbations are manifested by subacute respiratory deterioration with worsening hypoxemia in the setting of new radiographic abnormalities. The prognosis of patients with CTD having respiratory failure is often quite poor, highlighting the need for prompt and thorough clinical assessments to determine the underlying etiology and implementation of appropriate therapeutic strategies.
RaghuGCollardHREganJJ. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824.
2.
LeeHKKimDSYooB. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest. 2005;127(6):2019–2027.
3.
American Thoracic Society; European Respiratory Society. American thoracic society/European respiratory society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. This joint statement of the American thoracic society (ATS), and the European respiratory society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS executive committee, June 2001. Am J Respir Crit Care Med. 2002;165(2):277–304.
4.
FlahertyKRTravisWDColbyTV. Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med. 2001;164(9):1722–1727.
5.
FlahertyKRToewsGBTravisWD. Clinical significance of histological classification of idiopathic interstitial pneumonia. Eur Respir J. 2002;19(2):275–283.
6.
BourosDWellsAUNicholsonAG. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med. 2002;165(12):1581–1586.
7.
ParkJHKimDSParkIN. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med. 2007;175(7):705–711.
8.
KimEJElickerBMMaldonadoF. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 2010;35(6):1322–1328.
9.
TsuchiyaYTakayanagiNSugiuraH. Lung diseases directly associated with rheumatoid arthritis and their relation to outcome. Eur Respir J. 2011;37(6):1411–1417.
10.
KimEJCollardHRKingTEJr. Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern. Chest. 2009;136(5):1397–1405.
GabbayETaralaRWillR. Interstitial lung disease in recent onset rheumatoid arthritis. Am J Respir Crit Care Med. 1997;156(2 pt 1):528–535.
13.
DawsonJKFewinsHEDesmondJLynchMPGrahamDR. Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. Thorax. 2001;56(8):622–627.
14.
SaagKGKolluriSKoehnkeRK. Rheumatoid arthritis lung disease. Determinants of radiographic and physiologic abnormalities. Arthritis Rheum. 1996;39(10):1711–1719.
15.
AlexiouIGermenisAKoutroumpasAKontogianniATheodoridouKSakkasLI. Anti-cyclic citrullinated peptide-2 (CCP2) autoantibodies and extra-articular manifestations in Greek patients with rheumatoid arthritis. Clin Rheumatol. 2008;27(4):511–513.
16.
SakaidaH. IgG rheumatoid factor in rheumatoid arthritis with interstitial lung disease [in Japanese]. Ryumachi [Rheumatism]. 1995;35(4):671–677.
17.
SilvaCIMullerNL. Drug-induced lung diseases: most common reaction patterns and corresponding high-resolution CT manifestations. Semin Ultrasound CT MR. 2006;27(2):111–116.
18.
BilgiciAUlusoyHKuruOCelenkCUnsalMDanaciM. Pulmonary involvement in rheumatoid arthritis. Rheumatol Int. 2005;25(6):429–435.
19.
ShimizuYSunagaNDobashiK. Serum markers in interstitial pneumonia with and without Pneumocystis jirovecii colonization: a prospective study. BMC Infect Dis. 2009;9:47.
GabrielliAAvvedimentoEVKriegT. Scleroderma. N Engl J Med. 2009;360(19):1989–2003.
28.
SteenVDMedsgerTA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis. 2007;66(7):940–944.
29.
SchurawitzkiHStiglbauerRGraningerW. Interstitial lung disease in progressive systemic sclerosis: high-resolution CT versus radiography. Radiology. 1990;176(3):755–759.
30.
McNearneyTAReveilleJDFischbachM. Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors. Arthritis Rheum. 2007;57(2):318–326.
31.
GreidingerELFlahertyKTWhiteBRosenAWigleyFMWiseRA. African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease. Chest. 1998;114(3):801–807.
32.
MorelliSBarbieriCSgrecciaA. Relationship between cutaneous and pulmonary involvement in systemic sclerosis. J Rheumatol. 1997;24(1):81–85.
33.
GoldinJGLynchDAStrolloDC. High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease. Chest. 2008;134(2):358–367.
34.
Remy-JardinMRemyJWallaertBBatailleDHatronPY. Pulmonary involvement in progressive systemic sclerosis: sequential evaluation with CT, pulmonary function tests, and bronchoalveolar lavage. Radiology. 1993;188(2):499–506.
35.
OzbalkanZTopeliAKirazSOzturkMAErtenliICalguneriM. The contribution of underlying systemic rheumatic diseases to the mortality in patients admitted for intensive care: a matched cohort study. Clin Exp Rheumatol. 2004;22(2):223–226.
36.
PourratOBureauJMHiraMMartin BarbazFDescampsJMRobertR. Outcome of patients with systemic rheumatic diseases admitted to intensive care units: a retrospective study of 39 cases [in French]. Rev Med Interne. 2000;21(2):147–151.
QuinteroOLRojas-VillarragaAMantillaRDAnayaJM. Autoimmune diseases in the intensive care unit. an update. Autoimmun Rev. 2013;12(3):380–395.
39.
GerbinoAJGossCHMolitorJA. Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest. 2008;133(2):455–460.
Simeon-AznarCPFonollosa-PlaVTolosa-VilellaCSelva-O'CallaghanASolans-LaqueRVilardell-TarresM. Effect of mycophenolate sodium in scleroderma-related interstitial lung disease. Clin Rheumatol. 2011;30(11):1393–1398.
42.
ZamoraACWoltersPJCollardHR. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med. 2008;102(1):150–155.
43.
LiossisSNBounasAAndonopoulosAP. Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology (Oxford). 2006;45(8):1005–1008.
44.
JanssenNMKarnadDRGuntupalliKK. Rheumatologic diseases in the intensive care unit: epidemiology, clinical approach, management, and outcome. Crit Care Clin. 2002;18(4):729–748.
45.
FathiMDastmalchiMRasmussenELundbergIETornlingG. Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis. 2004;63(3):297–301.
46.
SolomonJSwigrisJJBrownKK. Myositis-related interstitial lung disease and antisynthetase syndrome. J Bras Pneumol. 2011;37(1):100–109.
47.
ArakawaHYamadaHKuriharaY. Nonspecific interstitial pneumonia associated with polymyositis and dermatomyositis: serial high-resolution CT findings and functional correlation. Chest. 2003;123(4):1096–1103.
48.
MiletiLMStrekMENiewoldTBCurranJJSweissNJ. Clinical characteristics of patients with anti-Jo-1 antibodies: a single center experience. J Clin Rheumatol. 2009;15(5):254–255.
49.
KoreedaYHigashimotoIYamamotoM. Clinical and pathological findings of interstitial lung disease patients with anti-aminoacyl-tRNA synthetase autoantibodies. Intern Med. 2010;49(5):361–369.
50.
FischerASwigrisJJdu BoisRM. Anti-synthetase syndrome in ANA and anti-Jo-1 negative patients presenting with idiopathic interstitial pneumonia. Respir Med. 2009;103(11):1719–1724.
51.
DouglasWWTazelaarHDHartmanTE. Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med. 2001;164(7):1182–1185.
52.
MarieIHachullaECherinP. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum. 2002;47(6):614–622.
53.
SuzukiYHayakawaHMiwaS. Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis. Lung. 2009;187(3):201–206.
54.
BallEMSavageEMPendletonA. Refractory anti-synthetase syndrome treated with rituximab. Rheumatology (Oxford). 2010;49(5):1013.
55.
ParambilJGMyersJLLindellRMMattesonELRyuJH. Interstitial lung disease in primary Sjogren syndrome. Chest. 2006;130(5):1489–1495.
56.
ItoINagaiSKitaichiM. Pulmonary manifestations of primary Sjogren's syndrome: a clinical, radiologic, and pathologic study. Am J Respir Crit Care Med. 2005;171(6):632–638.
57.
SwigrisJJFischerAGillisJMeehanRTBrownKK. Pulmonary and thrombotic manifestations of systemic lupus erythematosus. Chest. 2008;133(1):271–280.
58.
BertoliAMVilaLMApteM. Systemic lupus erythematosus in a multiethnic US Cohort LUMINA XLVIII: factors predictive of pulmonary damage. Lupus. 2007;16(6):410–417.
59.
BodolayESzekaneczZDevenyiK. Evaluation of interstitial lung disease in mixed connective tissue disease (MCTD). Rheumatology (Oxford). 2005;44(5):656–661.
60.
GunnarssonRAalokkenTMMolbergO. Prevalence and severity of interstitial lung disease in mixed connective tissue disease: a nationwide, cross-sectional study. Ann Rheum Dis. 2012;71(12):1966–1972.
61.
SaitoYTeradaMTakadaT. Pulmonary involvement in mixed connective tissue disease: comparison with other collagen vascular diseases using high resolution CT. J Comput Assist Tomogr. 2002;26(3):349–357.
62.
KozukaTJohkohTHondaO. Pulmonary involvement in mixed connective tissue disease: high-resolution CT findings in 41 patients. J Thorac Imaging. 2001;16(2):94–98.
63.
LeeJYimJJYangSC. Outcome of patients with connective tissue disease requiring intensive care for respiratory failure. Rheumatol Int. 2012;32(11):3353–3358.
64.
ThongBYTaiDYGohSKJohanA. An audit of patients with rheumatic disease requiring medical intensive care. Ann Acad Med Singapore. 2001;30(3):254–259.
65.
Christ-CrainMJaccard-StolzDBingisserR. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet. 2004;363(9409):600–607.
66.
Christ-CrainMStolzDBingisserR. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med. 2006;174(1):84–93.
67.
StolzDStulzAMullerBGratwohlATammM. BAL neutrophils, serum procalcitonin, and C-reactive protein to predict bacterial infection in the immunocompromised host. Chest. 2007;132(2):504–514.
68.
MaschmeyerGHaasACornelyOA. Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients. Drugs. 2007;67(11):1567–1601.
69.
SyrjalaHBroasMSuramoIOjalaALahdeS. High-resolution computed tomography for the diagnosis of community-acquired pneumonia. Clin Infect Dis. 1998;27(2):358–363.
70.
MoriSSugimotoM. Pneumocystis jirovecii infection: an emerging threat to patients with rheumatoid arthritis. Rheumatology (Oxford). 2012;51(12):2120–2130.
71.
WolfeFCaplanLMichaudK. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum. 2006;54(2):628–634.
72.
AokiYIwamotoMKamataY. Prognostic indicators related to death in patients with pneumocystis pneumonia associated with collagen vascular diseases. Rheumatol Int. 2009;29(11):1327–1330.
73.
KamataYNaraHKamimuraT. Rheumatoid arthritis complicated with acute interstitial pneumonia induced by leflunomide as an adverse reaction. Intern Med. 2004;43(12):1201–1204.
74.
LateefOShakoorNBalkRA. Methotrexate pulmonary toxicity. Expert Opin Drug Saf. 2005;4(4):723–730.
75.
SchwaiblmairMBehrWHaeckelTMarklBFoergWBerghausT. Drug induced interstitial lung disease. Open Respir Med J. 2012;6:63–74.
ParambilJGMyersJLAubryMCRyuJH. Causes and prognosis of diffuse alveolar damage diagnosed on surgical lung biopsy. Chest. 2007;132(1):50–57.
85.
ParambilJGMyersJLRyuJH. Diffuse alveolar damage: uncommon manifestation of pulmonary involvement in patients with connective tissue diseases. Chest. 2006;130(2):553–558.
86.
ChenIJJan WuYJLinCW. Interstitial lung disease in polymyositis and dermatomyositis. Clin Rheumatol. 2009;28(6):639–646.
87.
SilvaCIMullerNL. Interstitial lung disease in the setting of collagen vascular disease. Semin Roentgenol. 2010;45(1):22–28.
88.
OgawaDHashimotoHWadaJ. Successful use of cyclosporin A for the treatment of acute interstitial pneumonitis associated with rheumatoid arthritis. Rheumatology (Oxford). 2000;39(12):1422–1424.
89.
TanakaFOriguchiTMigitaK. Successful combined therapy of cyclophosphamide and cyclosporine for acute exacerbated interstitial pneumonia associated with dermatomyositis. Intern Med. 2000;39(5):428–430.
90.
ClawsonKOddisCV. Adult respiratory distress syndrome in polymyositis patients with the anti-Jo-1 antibody. Arthritis Rheum. 1995;38(10):1519–1523.
